This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
Get a free vaccination guide and nearby clinic recommendations — straight to your inbox.
How serious?
Risk of death
No
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
Transmitted by Culex mosquitoes, active from dusk to dawn. No vaccine or specific treatment is available — prevention through mosquito bite avoidance is your only protection. Risk areas include Mediterranean Europe, Middle East, Africa, and North America in summer. Use mosquito repellent in the evening and sleep with window screens or AC.
Mosquito-borne flavivirus infection. Most infections are asymptomatic (~80%); ~20% develop West Nile fever; <1% develop severe neuroinvasive disease (encephalitis, meningitis, acute flaccid paralysis) with significant mortality.
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Fever | 95% | Mild | Early |
| Fatigue | 80% | Mild | Early |
| Headache | 85% | Mild | Early |
| Maculopapular rash | 50% | Mild | Early |
| Malaise | 70% | Mild | Early |
| Myalgia | 65% | Mild | Early |
| Arthralgia | 40% | Mild | Early |
| Chills | 30% | Mild | Early |
| Diarrhea | 20% | Mild | Early |
| Eye pain | 12% | Mild | Early |
| Loss of appetite | 55% | Mild | Early |
| Nausea | 40% | Mild | Early |
| Swollen lymph nodes | 15% | Mild | Early |
| Vomiting | 25% | Mild | Early |
| Altered consciousness | 1.5% | Critical | Peak |
| Confusion | 2% | Severe | Peak |
| Neck stiffness | 3% | Severe | Peak |
| Paralysis | 0.7% | Critical | Peak |
| Severe headache | 4% | Severe | Peak |
| Tremor | 1.8% | Moderate | Peak |
| Dizziness | 1.5% | Moderate | Peak |
| Photophobia | 2.5% | Moderate | Peak |
| Seizures | 0.8% | Critical | Peak |
West Nile virus (WNV) is an arthropod-borne flavivirus belonging to the Japanese encephalitis serocomplex of the family Flaviviridae. First isolated in 1937 from a febrile woman in the West Nile district of Uganda, the virus has since spread to become one of the most widely distributed arboviruses globally.
WNV is maintained in a mosquito-bird enzootic cycle, with Culex species mosquitoes serving as the primary vectors. Over 300 bird species can serve as amplifying hosts, with corvids (crows, jays) being particularly susceptible. Humans and horses are incidental dead-end hosts who do not develop sufficient viremia to perpetuate transmission.
The virus is now endemic across Africa, the Middle East, Europe, South and Central Asia, Oceania, and the Americas. Since its introduction to North America in 1999, WNV has become the leading cause of arboviral neuroinvasive disease in the United States, with over 55,000 reported cases and 2,700 deaths through 2023.
Approximately 80% of human infections are asymptomatic. Of those who develop symptoms, roughly 20% experience West Nile fever, a self-limiting febrile illness. Less than 1% of all infected individuals develop neuroinvasive disease, which includes meningitis, encephalitis, and acute flaccid paralysis. Despite this low percentage, neuroinvasive disease carries significant morbidity and mortality.
Clinical Overview
West Nile virus infection presents across a broad clinical spectrum, from asymptomatic infection to fatal encephalitis. Understanding this spectrum is essential for clinicians working in endemic areas and for travelers to affected regions.
Key Clinical Facts:
Causative agent: West Nile virus (Flavivirus, family Flaviviridae)
Transmission: Bite of infected Culex mosquitoes; rare cases via blood transfusion, organ transplant, transplacental, and laboratory exposure
Incubation period: 2-14 days (typically 2-6 days)
Attack rate: ~20% develop symptomatic illness; <1% develop neuroinvasive disease
Case fatality rate: ~10% overall for neuroinvasive disease (meningitis ~2-5%, encephalitis ~10-15%, higher in elderly)
Seasonality: Peak transmission during warm months (June-October in temperate zones)
Global Significance:
WNV is a WHO-notifiable condition in many countries. Annual epidemics occur throughout the Mediterranean basin, southeastern Europe, and North America. The 2018 European epidemic resulted in over 2,000 confirmed cases, the largest recorded on the continent. Climate change is expanding the geographic range of competent vector species, increasing the risk for previously unaffected regions.
At-Risk Populations:
Persons over 60 years of age, immunocompromised individuals, and those with chronic kidney disease or diabetes are at substantially higher risk of neuroinvasive disease and death. Outdoor workers, campers, and travelers to endemic regions during peak mosquito season face elevated exposure risk.
Emergency Warning Signs
West Nile virus can rapidly progress to life-threatening neuroinvasive disease. Seek immediate medical attention if any of the following signs develop, particularly in persons over 60 or those who are immunocompromised:
Neurological Emergency Signs:
Severe headache that is sudden in onset, unresponsive to analgesics, or the "worst headache of my life"
Neck stiffness (nuchal rigidity) — inability to touch chin to chest
Altered mental status — confusion, disorientation, lethargy, or stupor
Seizures — any new-onset seizure activity
Focal neurological deficits — limb weakness, facial droop, slurred speech
Acute onset limb weakness — especially asymmetric, flaccid paralysis of one or more limbs
Tremors or involuntary movements — especially parkinsonian features
High fever (>40°C / 104°F) with neurological symptoms
Additional Red Flags:
Difficulty breathing or respiratory failure (may indicate brainstem involvement or diaphragmatic weakness)
Visual disturbances (optic neuritis, chorioretinitis)
Inability to swallow or protect airway
Rapid clinical deterioration despite supportive care
Important: Neuroinvasive disease can progress rapidly within hours. Early hospitalization with access to ICU-level care significantly improves outcomes. The case fatality rate for West Nile encephalitis is approximately 10-15%, rising to 15-29% in patients over 70 years of age.
Most common signs and symptoms
Symptom Presentation
West Nile virus infection manifests in three distinct clinical syndromes of increasing severity.
1. West Nile Fever (Non-Neuroinvasive Disease)
This is the most common symptomatic presentation, occurring in approximately 20% of infected individuals. Symptoms typically appear 2-6 days after the mosquito bite and include:
Acute-onset fever (often >39°C / 102°F)
Headache, often severe and frontal
Fatigue and malaise, which may persist for weeks
Body aches and myalgia
Nausea, vomiting, and occasionally diarrhea
Transient maculopapular rash (occurs in ~25-50% of febrile cases), typically on the trunk and extremities
Lymphadenopathy
The illness is generally self-limiting, resolving within 3-6 days, though fatigue may persist for weeks to months.
2. West Nile Neuroinvasive Disease (WNND)
Affecting less than 1% of all infected persons, WNND presents in three forms:
West Nile meningitis: Fever, headache, neck stiffness, photophobia, CSF pleocytosis. Generally favorable prognosis.
West Nile encephalitis: Altered mental status, seizures, movement disorders (tremor, myoclonus, parkinsonism), cranial nerve palsies. Higher mortality.
West Nile acute flaccid paralysis: Asymmetric limb weakness resembling poliomyelitis, due to anterior horn cell damage. Often permanent.
3. Other Rare Manifestations
Myocarditis, pancreatitis, hepatitis
Rhabdomyolysis
Optic neuritis and chorioretinitis
Guillain-Barre-like syndrome
Knowing the symptoms is the first step to a quick response.
Disease Course and Progression
The natural history of West Nile virus infection follows a characteristic timeline from exposure through resolution or chronic sequelae.
Exposure and Incubation (Days 0-14):
Virus is inoculated by the bite of an infected Culex mosquito
Incubation period is typically 2-6 days, but can range from 2-14 days
Longer incubation periods (up to 21 days) reported in immunocompromised patients
Virus replicates in dendritic cells at the bite site, then disseminates via lymphatics and blood
Viremic Phase (Days 1-7 post-symptom onset):
Viremia is typically brief (1-7 days) and low-level in immunocompetent hosts
Serum viral loads are generally below the threshold for mosquito transmission (dead-end host)
In immunocompromised patients, viremia may be prolonged for weeks
Febrile Phase (Days 2-10 post-symptom onset):
Abrupt onset of fever, headache, myalgia
Rash may appear during this phase
Most patients (~99% of symptomatic cases) recover during this phase
Fever typically resolves within 3-6 days
Neuroinvasive Phase (Days 3-15, when it occurs):
Virus crosses the blood-brain barrier, likely through hematogenous spread or retrograde axonal transport
Meningitis: acute onset of neck stiffness, photophobia, headache
Encephalitis: progressive confusion, tremor, movement disorders, seizures, coma
Acute flaccid paralysis: sudden onset of asymmetric limb weakness, may involve respiratory muscles
Peak neurological deficits typically occur within 1-7 days of CNS symptom onset
Recovery Phase (Weeks to Months):
West Nile fever: recovery within 1-2 weeks, residual fatigue common
Meningitis: generally good recovery over 2-4 weeks
Encephalitis: slow recovery over months; cognitive and motor deficits may be permanent
Acute flaccid paralysis: motor recovery is slow and often incomplete over 6-12 months
How this disease is identified
Diagnosis
West Nile virus diagnosis requires a combination of clinical suspicion, epidemiological context, and laboratory confirmation. The differential diagnosis is broad and includes other arboviral infections, bacterial meningitis, and autoimmune conditions.
Laboratory Diagnostic Methods:
IgM Antibody Detection (ELISA):
Plaque Reduction Neutralization Test (PRNT):
RT-PCR (Nucleic Acid Amplification):
Cerebrospinal Fluid Analysis:
Imaging:
MRI may show T2/FLAIR signal abnormalities in the thalami, basal ganglia, brainstem, and spinal cord anterior horns
Findings are present in approximately 50-70% of WNND cases
Available treatment methods
Treatment and Management
There is no specific antiviral therapy approved for West Nile virus infection. Management is entirely supportive and depends on disease severity.
Mild Disease (West Nile Fever):
Rest and adequate hydration
Antipyretics (acetaminophen/paracetamol) for fever and pain
Avoidance of aspirin and NSAIDs until dengue is excluded (if co-endemic)
Most patients recover fully within 1-2 weeks, though fatigue may persist for months
Neuroinvasive Disease (Hospitalized):
Intravenous fluids for hydration and electrolyte management
Intensive monitoring of neurological status and respiratory function
Airway management: Patients with encephalitis or acute flaccid paralysis may require intubation and mechanical ventilation (up to 10-15% of hospitalized WNND cases)
Seizure management: IV benzodiazepines followed by levetiracetam or phenytoin
Raised intracranial pressure: Osmotic agents (mannitol, hypertonic saline) if indicated
Prevention of complications: DVT prophylaxis, pressure ulcer prevention, aspiration precautions
Investigational Therapies: Several agents have been studied but none has demonstrated definitive efficacy:
Intravenous immunoglobulin (IVIG): Some observational data suggest benefit, particularly in immunocompromised patients. Not FDA-approved for this indication.
Interferon alpha-2b: Mixed results in clinical trials
Monoclonal antibodies: Under development; some showing promise in preclinical studies
High-dose ribavirin: In vitro activity but no clinical benefit demonstrated
Rehabilitation: Patients with neuroinvasive disease, particularly acute flaccid paralysis, often require prolonged physical therapy and rehabilitation. Full motor recovery occurs in less than 50% of paralysis cases.
Most cases are effectively treated with early diagnosis.
How to protect yourself
Prevention Strategies
There is currently no approved human vaccine for West Nile virus. Prevention relies entirely on reducing mosquito exposure and community-level vector control.
Personal Protective Measures:
Use EPA-registered insect repellents: DEET (20-30%), picaridin (20%), IR3535, or oil of lemon eucalyptus (OLE/PMD). Apply to exposed skin when outdoors.
Wear protective clothing: Long sleeves, long pants, and socks during peak mosquito activity (dusk and dawn for Culex species)
Use permethrin-treated clothing and gear: Permethrin can be applied to clothing, boots, and tents; remains effective through several washes
Sleep under insecticide-treated bed nets or in air-conditioned/screened rooms, especially in endemic areas without reliable screening
Avoid outdoor activity during peak biting hours: Culex mosquitoes are most active from dusk to dawn
Environmental and Household Measures:
Eliminate standing water around the home (flowerpots, gutters, tires, bird baths)
Maintain window and door screens in good repair
Use mosquito-safe larvicides (e.g., Bti dunks) in ornamental water features
Support community-level integrated vector management programs
Blood and Organ Safety:
All donated blood in the United States and many European countries is screened for WNV by nucleic acid testing (NAT) since 2003
Organ transplant recipients are at elevated risk; donor screening protocols are in place
Vaccine Development:
Several candidate vaccines are in clinical trials, including chimeric live-attenuated, DNA, and inactivated whole-virus platforms
An equine vaccine is licensed and widely used in veterinary medicine
No human vaccine is expected to be licensed before 2027-2028
Preparation is the best protection.
Travel Advice
West Nile virus poses a risk to travelers visiting endemic regions during mosquito season. While the overall risk of severe disease is low, travelers should be well-informed about prevention and symptom recognition.
Risk Assessment by Region:
North America: Seasonal risk (June-October), particularly in central and western US states
Europe: Mediterranean basin, southeastern Europe (Greece, Italy, Romania, Serbia). Peak July-October. Expanding northward with climate change.
Middle East: Israel, Turkey, Iran — year-round risk in some areas
Africa: Endemic throughout sub-Saharan Africa; risk is year-round in equatorial regions
South/Central Asia: India, Pakistan — underreported but present
Pre-Travel Recommendations:
During Travel:
Apply repellent consistently, especially from dusk to dawn
Stay in well-screened or air-conditioned accommodations
Be particularly vigilant in rural and periurban settings near standing water
Avoid sleeping outdoors without a bed net in endemic areas
Post-Travel:
Seek medical attention if fever, headache, or neurological symptoms develop within 2-14 days of return from an endemic area
Inform the clinician of travel history and potential arboviral exposure
Report to travel health surveillance if directed by local health authorities
Special Populations: Travelers over 60 years of age and immunocompromised individuals should exercise extra caution, as they face significantly higher risk of neuroinvasive disease and death.
Statistics and geographic data
Epidemiology
West Nile virus is the most widely distributed arbovirus in the world, found across all continents except Antarctica.
Global Distribution and Burden:
Present in Africa, Europe, the Middle East, Central and South Asia, Oceania, and the Americas
Estimated tens of thousands of neuroinvasive cases annually worldwide (significant underreporting)
United States: Over 55,000 reported cases and 2,700 deaths since 1999. Annual average: ~2,000 cases reported (estimated true incidence 30-70x higher)
Europe: Major epidemics in 2010, 2012, 2018 (record 2,083 cases), and recurrent seasonal activity in Mediterranean and southeastern European countries
Africa and Middle East: Endemic, with sporadic large outbreaks (e.g., Israel 2000, Sudan 2002)
Transmission Dynamics:
Primary cycle: Mosquito-bird-mosquito (enzootic). Culex pipiens, Cx. quinquefasciatus, Cx. tarsalis are principal vectors.
Bridge vectors: Some Aedes and Culex species feed on both birds and mammals, bridging the cycle to humans
Non-vector transmission: Blood transfusion (~1 per 1,000-3,000 donations during peak season before screening), organ transplant, transplacental (rare), breast milk (extremely rare), laboratory accidents
Seasonality:
Temperate regions: June-October (peaking August-September)
Tropical/subtropical regions: Year-round with peaks during rainy seasons
Outbreaks correlate with hot, dry summers followed by periods of rain
Surveillance:
Many countries maintain sentinel surveillance through avian mortality monitoring (especially corvids), mosquito pool testing, equine cases, and human case reports
Blood donor screening (NAT) serves as an additional surveillance tool
Climate Change Impact:
Rising temperatures are extending the geographic range of Culex mosquitoes northward in Europe and North America
Warmer winters reduce mosquito overwintering mortality, increasing populations the following season
Altered rainfall patterns affect breeding site availability and outbreak dynamics
Who is most at risk
Risk Factors
Risk factors for West Nile virus infection and progression to severe disease operate at both the exposure level and the host level.
Risk Factors for Exposure/Infection:
Geographic location: Living in or traveling to endemic areas during transmission season
Season: Peak risk during warm months when Culex mosquito populations are highest (typically June-October in temperate zones)
Outdoor activities: Camping, hiking, farming, gardening, and other activities that increase mosquito exposure
Occupational exposure: Agricultural workers, forestry workers, military personnel in endemic areas
Peridomestic environment: Proximity to standing water, lack of window screens, poor waste management
Urbanization patterns: Culex pipiens thrives in urban and suburban environments
Risk Factors for Severe/Neuroinvasive Disease:
Age >60 years: The single strongest risk factor for neuroinvasive disease and death. Persons over 70 have a CFR of 15-29% for WNND.
Immunosuppression:
Chronic medical conditions:
Genetic factors: Certain HLA alleles and polymorphisms in innate immune genes (e.g., CCR5-delta32, OAS1) have been associated with susceptibility to neuroinvasive disease
Protective Factors:
Prior WNV infection confers long-lasting (likely lifelong) immunity
Prior flavivirus vaccination (e.g., yellow fever, Japanese encephalitis) may provide partial cross-protection, though evidence is limited
Consistent use of insect repellent reduces risk by 80-90%
Potential complications
Complications
While most West Nile virus infections are asymptomatic or self-limiting, neuroinvasive disease can result in serious, life-altering complications.
Acute Neurological Complications:
Meningoencephalitis: Combined meningeal and parenchymal inflammation, occurring in the majority of hospitalized WNND patients. May result in cerebral edema and herniation.
Acute flaccid paralysis (AFP): Occurs in approximately 10-15% of WNND cases. Results from anterior horn cell damage, analogous to poliovirus. Respiratory muscle involvement may necessitate prolonged mechanical ventilation.
Seizures: Occur in 5-15% of encephalitis cases and may be refractory to standard anticonvulsants.
Cerebral edema and raised intracranial pressure: Life-threatening complication requiring ICU management.
Chronic Neurological Sequelae (in ~50% of WNND survivors):
Cognitive impairment: Memory loss, difficulty concentrating, and executive dysfunction are common, reported in 40-70% of survivors at 1-year follow-up
Motor deficits: Persistent weakness, gait instability, and tremor. AFP-related weakness is often permanent.
Neuropsychiatric disorders: Depression (up to 75% at 1 year), anxiety, PTSD, and personality changes
Chronic fatigue: Debilitating fatigue lasting months to years, affecting quality of life
Movement disorders: Parkinsonism, myoclonus, and intention tremor, which may be permanent
Other Complications:
Myocarditis: Rare but potentially fatal; presents with arrhythmias and heart failure
Rhabdomyolysis: Skeletal muscle breakdown with risk of acute kidney injury
Ocular complications: Chorioretinitis (occurs in up to 80% of WNND patients when examined ophthalmoscopically), multifocal choroiditis, optic neuritis. May result in permanent visual impairment.
Hepatitis and pancreatitis: Uncommon but documented
Secondary infections: Nosocomial pneumonia, urinary tract infections, and sepsis in patients with prolonged hospitalization
Impact on Quality of Life: Studies show that WNND survivors have significantly reduced quality of life scores at 1-5 years post-infection, comparable to stroke survivors. Many are unable to return to pre-illness functional status.
Expected outcomes and recovery
Prognosis and Outcomes
The prognosis for West Nile virus infection varies dramatically depending on disease severity and patient characteristics.
West Nile Fever:
Excellent prognosis with full recovery expected
Self-limiting illness, resolving in 3-6 days
Prolonged fatigue reported in up to 50% of cases, lasting weeks to months
No long-term sequelae in the vast majority of cases
Neuroinvasive Disease — Overall:
Case fatality rate: ~10% overall for neuroinvasive disease (meningitis ~2-5%, encephalitis ~10-15%)
CFR varies by presentation: meningitis ~2-5%, encephalitis ~12-20%, acute flaccid paralysis ~5-10%
Age is the strongest predictor: CFR rises to 15-29% in patients over 70 years
Immunosuppression (organ transplant recipients, HIV/AIDS) associated with higher mortality and more severe disease
Long-Term Sequelae: Approximately 50% of neuroinvasive disease survivors experience persistent neurological and functional deficits, including:
Cognitive impairment (memory, concentration, executive function)
Persistent weakness and fatigue
Depression and mood disorders (reported in up to 75% at 1 year)
Movement disorders (tremor, parkinsonism)
Chronic pain syndromes
Acute Flaccid Paralysis Outcomes:
Only 30-40% of patients with WNV acute flaccid paralysis achieve significant motor recovery
Residual weakness is common and often permanent
Respiratory muscle involvement may require prolonged ventilator support
Recovery, when it occurs, is typically slow over 6-12 months
Predictors of Poor Outcome:
Age >60 years
Diabetes mellitus, chronic kidney disease
Immunosuppression
Altered consciousness at presentation
Need for mechanical ventilation
The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useKnow which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.